Diagnostic Accuracy of Early Computed Tomographic Coronary Angiography to Detect Coronary Artery Disease After Out-of-Hospital Circulatory Arrest |
|
Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. |
|
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial |
|
Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. |
|
Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure |
|
Effects of intensive blood-pressure control in type 2 diabetes mellitus |
|
Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group |
|
Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study |
|
Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial |
|
Evaluating effects of treatment in subgroups of patients within a clinical trial: the case of non-Q-wave myocardial infarction and beta blockers. |
|
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. |
|
Garlic tablets are ineffective in hypercholesterolemia |
|
Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. |
|
Hemostatic effects of 1 mg daily warfarin on post CABG patients. Post CABG Studies Investigators. |
|
How can clinical researchers quantify the value of their proposed comparative research? |
|
How cost-effective are new preventive strategies for cardiovascular disease? |
|
Impact of supplemental site grants to increase African American accrual for the Selenium and Vitamin E Cancer Prevention Trial |
|
Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperat |
|
Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study |
|
Long-term effects of intensive glucose lowering on cardiovascular outcomes |
|
Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial |
|
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. |
|
Occupational screenings: recruitment from private industry |
|
Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme |
|
Predictive value of the exercise tolerance test for mortality in North American men: the Lipid Research Clinics Mortality Follow-up Study |
|
Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. |
|
Progression of cardiovascular damage: the role of renin-angiotensin system blockade |
|
Racial differences in outcome and treatment effect in congestive heart failure |
|
Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. |
|
Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial |
|
Re: Hawkins RG, Houston MC Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States? A hypothesis. Am J Hypertens. 2005 Jun;18(6):744-9 |
|
Relationship between coronary artery and descending thoracic aortic calcification as detected by computed tomography: the Multi-Ethnic Study of Atherosclerosis |
|
Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries |
|
Response to Comment on the FLAT-SUGAR Trial Investigators. Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk. |
|
Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study |
|
Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration |
|
Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT |
|
Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT |
|
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy |
|
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial |
|
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. |
|
Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus |
|
The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: Insights from the COMPASS Trial |
|
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin |
|
Safety profile of extended-release niacin in the AIM-HIGH trial |
|
Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Tria |
|
Smoking, high SBP and cholesterol levels were associated with increased risk of carotid artery stenosis |
|
Smoking, physical activity, and other predictors of endurance and heart rate response to exercise in asymptomatic hypercholesterolemic men. The Lipid Research Clinics Coronary Primary Prevention Trial |
|
Spironolactone for heart failure with preserved ejection fraction |
|
Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT. |
|
Summary of clinical and laboratory data of study subjects with and without DCE-MRI plaque measurements in the AIM-HIGH clinical trial. |
|
Surrogate endpoints in clinical trials: cardiovascular diseases. |
|
The systolic hypertension in the elderly program. Implications for nursing practice and research |
|
Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular disease |
|
Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the Studies of Left Ventricular Dysfunction. |
|
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis |
|
Urinary Catalytic Iron in Patients with Type 2 Diabetes without Microalbuminuria--a Substudy of the ACCORD Trial |
|
Use of lipid lowering agents in the prevention of cardiovascular disease. |
|
Uso de los agentes hipolipemiantes en la prevención de la enfermedad cardiovascular |
|
Venous thromboembolism in association with features of the metabolic syndrome. |
|